Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00171899
Status:
COMPLETED
Last Update Posted:
2017-02-23
First Post:
2005-09-13
Brief Title:
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive Ph Chronic Myelogenous Leukemia CML
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Key Dates - Follows AllAPIJSON File Order
Start Date:
2005-04
Start Date Type:
None
Primary Completion Date:
2007-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2007-06
Completion Date Type:
ACTUAL
First Submit Date:
2005-09-13
First Submit QC Date:
September 13 2005
Study First Post Date:
2005-09-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-02-21
Last Update Post Date:
2017-02-23
Last Update Post Date Type:
ACTUAL